18 marzo 2015
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/z9ngpQmfdkc/150318074052.htm
